BIOVENTIX PLC ORD GBP0.05
Symbol: BVXP
Streaming is not available when market closed. Some prices may be as at close of business from the previous working day.
Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.
Invest in this share within an ISA, JISA, SIPP or Investment Account
Overview
Core Data
Latest Dividend Information
| Ex-Dividend Date | 10 Apr 2025 |
| Pay Date | 25 Apr 2025 |
| Total Dividends - Year to Date | 157 |
| Dividend Yield (%) | 5.8692 |
Historical Data & Ratios
| Avg Volume Over 10 Days | 0.0111 |
| Market Cap (M) | 135.3239 |
| Price/Earnings (PE) | 0 |
| Earnings Per Share | 150.3 |
| Revenue Per Share | 2.5688 |
| Return on Equity % | 67.2864 |
1 Month Performance Chart
Cost and Charges Information
This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product
Account Type
Annual charges
These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate
| Cost Category | % of Investment | lump sum costs |
|---|---|---|
Our annual fee
Our annual feeIncludes our platform fee at 0.30% per annum (excluding Charles Stanley Multi Asset Funds and anycash held). The min fee is £60, the max is £600 per annum, plus SIPP administration fee (if applicable, only charged if < £30,000 held) – see here |
0.30% | |
Dealing charges
Dealing chargesAny one-off commission charges associated with investing. Note that government taxes and levies are not included. This does not include any commission credits you may have available |
N/A | |
Product provider costs
Product provider costsProduct provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs |
N/A | N/A |
Total (£)
Total (£)Costs per annum displayed in monetary value |
||
Total (%)
Total (%)Costs per annum displayed as a percentage of investment value |
||
Cumulative effect of charges on your investment's return
This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges
| lump sum invested with an assumed growth rate of | 1 year | years |
|---|---|---|
What you might get back at with no charges applied
What you might get back at with no charges appliedThese are the illustrative values of a investment after growth and no costs applied at the end of the defined period |
||
Annual charges
Annual chargesThese are the annual costs based on an initial investment amount of assuming a net zero growth rate |
||
Effect of charges on return (%)
Effect of charges on return (%)These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate |
||
Effect of charges on return (£)
Effect of charges on return (£)These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate |
||
What you might get back at with charges applied
What you might get back at with charges appliedThese are the illustrative values of a investment after growth and costs at the end of the defined period |
This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use
Charts
Company
Business Summary
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Financial Summary
BRIEF: For the fiscal year ended 30 June 2024, Bioventix PLC revenues increased 6% to £13.6M. Net income decreased 3% to £8.1M. Revenues reflect REST OF THE WORLD segment increase of 14% to £11.7M. Net income was offset by Administrative Expenses increase of 13% to £2M (expense), Difference on Foreign Exchange increase of 15% to £42K (expense). Dividend per share increased from £1.52 to £1.55.
Financials
Income Statement - All values are in GBP (M).
|
Year Ending |
30/06/2024 |
30/06/2023 |
30/06/2022 |
30/06/2021 |
30/06/2020 |
30/06/2019 |
|---|---|---|---|---|---|---|
| Total Revenue | 13.61 | 12.82 | 11.72 | 10.93 | 10.31 | 9.29 |
| Gross profit | 12.68 | 11.99 | 11.01 | 10.11 | 9.49 | 8.41 |
| Operating Profit/Loss | 10.40 | 10.03 | 9.27 | 8.09 | 8.18 | 6.93 |
| Profit Before Tax | 10.60 | 10.13 | 9.28 | 8.12 | 8.23 | 6.97 |
| Profit After Tax | 8.10 | 8.37 | 7.67 | 6.73 | 7.20 | 5.86 |
| Equity Holders of Parent Company | 8.10 | 8.37 | 7.67 | 6.73 | 7.20 | 5.86 |
| Minority Interest | NIL | NIL | NIL | NIL | NIL | NIL |
Balance Sheet - All values are in GBP (M).
|
Year Ending |
30/06/2024 |
30/06/2023 |
30/06/2022 |
30/06/2021 |
30/06/2020 |
30/06/2019 |
|---|---|---|---|---|---|---|
| Total Non-Current Assets | 0.90 | 1.19 | 1.30 | 1.45 | 1.33 | 0.90 |
| Total Current Assets | 12.83 | 12.10 | 11.81 | 11.45 | 11.97 | 10.71 |
| Total Assets | 13.73 | 13.28 | 13.12 | 12.91 | 13.30 | 11.61 |
| Total Liabilities | 1.73 | 1.22 | 1.30 | 1.09 | 0.78 | 0.79 |
| Total Net Assets | 12.00 | 12.06 | 11.82 | 11.82 | 12.52 | 10.83 |
| Shareholders Funds | 12.00 | 12.06 | 11.82 | 11.82 | 12.52 | 10.83 |
| Minority Interests | NIL | NIL | NIL | NIL | NIL | NIL |
| Total Equity | 12.00 | 12.06 | 11.82 | 11.82 | 12.52 | 10.83 |
Outlook
Forecasts
| Year | 2025 |
|---|---|
| Revenue | £13.50mn |
| Pre-tax-Profit | £10.10mn |
| EPS | £1.52p |
| EPS Growth | -2.33% |
| P/E | 16.5 |
| PEG Ratio | -7.07 |
| Dividend | 155.00p |
| Yield | 0.00% |
Time & Sales
All prices are in GBX and times are in GMT. Last 20 trades shown. Trade type is estimated and should be treated as indicative only.
| Date | Time | Price | Volume | Type |
|---|---|---|---|---|
| 2 May 2025 | 16:25 | 2,692 | 915 | Buy |
| 2 May 2025 | 16:19 | 2,725 | 1,000 | Buy |
| 2 May 2025 | 16:17 | 2,745 | 1,225 | Buy |
| 2 May 2025 | 16:10 | 2,748 | 17 | Buy |
| 2 May 2025 | 16:04 | 2,688 | 130 | Buy |
| 2 May 2025 | 16:02 | 2,745 | 17 | Buy |
| 2 May 2025 | 15:54 | 2,745 | 75 | Buy |
| 2 May 2025 | 15:43 | 2,735 | 72 | Buy |
| 2 May 2025 | 15:39 | 2,725 | 1,000 | Buy |
| 2 May 2025 | 15:18 | 2,735 | 8 | Buy |
| 2 May 2025 | 15:17 | 2,725 | 300 | Buy |
| 2 May 2025 | 15:11 | 2,735 | 100 | Buy |
| 2 May 2025 | 15:07 | 2,729 | 146 | Buy |
| 2 May 2025 | 14:38 | 2,725 | 500 | Buy |
| 2 May 2025 | 14:17 | 2,725 | 300 | Buy |
| 2 May 2025 | 14:11 | 2,725 | 329 | Buy |
| 2 May 2025 | 14:08 | 2,720 | 39 | Buy |
| 2 May 2025 | 14:07 | 2,720 | 35 | Buy |
| 2 May 2025 | 14:02 | 2,670 | 830 | Sell |
Selected data supplied by Thomson Reuters © View restrictions.